SCHEMBL5253141

SCHEMBL5253141

Nc1onc2cccc(-c3ccc(NC(=O)Nc4cccc(Br)c4)cc3)c12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 19/20 0.70
KIT P10721 12/20 0.70
FLT3 P36888 16/20 0.62
PLK4 O00444 3/20 0.62
AURKA O14965 3/20 0.62
ROCK2 O75116 3/20 0.62
RPS6KA5 O75582 3/20 0.62
MAP4K4 O95819 3/20 0.62
CSF1R P07333 3/20 0.62
LYN P07948 3/20 0.62
RET P07949 3/20 0.62
FGFR1 P11362 3/20 0.62
FLT1 P17948 3/20 0.62
RPS6KB1 P23443 3/20 0.62
EPHA2 P29317 3/20 0.62
AXL P30530 3/20 0.62
FLT4 P35916 3/20 0.62
FRK P42685 3/20 0.62
CLK2 P49760 3/20 0.62
BLK P51451 3/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1383101 0.89 KDR (0.67) KDRKITFLT3PLK4AURKA
SCHEMBL1383479 0.87 KDR (0.70) KDRKITFLT3PLK4AURKA
SCHEMBL4736063 0.87 KDR (0.70) KDRKITFLT3AURKAROCK2
SCHEMBL1383493 0.87 KDR (0.72) KDRKITFLT3PLK4AURKA
SCHEMBL4738818 0.84 KDR (0.55) KDRKITFLT3PDGFRBPDGFRA
SCHEMBL4736486 0.84 KDR (0.72) KDRKITFLT3PLK4AURKA
SCHEMBL4740220 0.84 KDR (0.72) KDRKITFLT3PLK4AURKA
SCHEMBL4738714 0.84 KDR (0.63) KDRKITFLT3AURKAAURKB
SCHEMBL1382612 0.84 KDR (0.68) KDRKITFLT3CSF1RLYN
SCHEMBL4737316 0.84 KDR (0.68) KDRKITFLT3CSF1RLYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO claimed